Buy TEM by Aug 31, 2026.

The company presented 37 accepted abstracts at ASCO 2026, focused on using AI, genomic data, clinical records, imaging, pathology, and real-world outcomes to improve cancer treatment decisions. That matters because oncology is still full of messy decision points: which therapy to use, which patients are most likely to respond, who should be matched to a trial, and when disease signals are showing up earlier than standard tools can catch. The investment case is basically this: * Tempus is not just …